Oncoheroes 
Welcome,         Profile    Billing    Logout  
  Products    Diseases   Products    Trials    News 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
stenoparib (2X-121) / Allarity Therap, Oncoheroes
2019-002071-34: Allocation of patients with relapse of cancer to treatment with new drugs based on tumor biopsy

Not yet recruiting
2
40
Europe
LiPlaCis, Irofulven, 2X-121, Concentrate for dispersion for infusion, Concentrate for solution for infusion, Capsule, hard
Vejle Hospital, Vejle Hospital, Oncology Venture
Breast cancer Ovarian cancer Lung cancer Colorectal cancer Prostate cancer Pancreatic cancer, Breast cancer Ovarian cancer Lung cancer Cancer of the colon and rectum Prostate cancer Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
PREDICT 2X-121, NCT03878849: Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

Active, not recruiting
2
40
US
2X-121, E7449, MGI25036
Allarity Therapeutics, Alcedis GmbH, Amarex Clinical Research
Advanced Ovarian Cancer
03/27
09/27
NCT03562832 / 2017-003508-39: Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Active, not recruiting
2
30
Europe
PARP inhibitor 2X-121
Allarity Therapeutics, Smerud Medical Research International AS, Danish Breast Cancer Cooperative Group
Metastatic Breast Cancer
04/24
08/24
Relapsed SCLC, NCT06681220: Biomarker Directed Trial of Temozolomide and Stenoparib in

Not yet recruiting
1/2
166
US
Stenoparib/Temozolomide, Stenoparib/TEMODAR, Lurbinectedin, Zepzelca
VA Office of Research and Development
Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
12/29
12/30
NCT05571969: Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Suspended
1
40
US
2X-121 and dovitinib
Allarity Therapeutics, Amarex Clinical Research
Advanced Solid Tumors
10/24
12/25
dovitinib (TKI258) / Novartis, Oncoheroes
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
stenoparib (2X-121) / Allarity Therap, Oncoheroes
2019-002071-34: Allocation of patients with relapse of cancer to treatment with new drugs based on tumor biopsy

Not yet recruiting
2
40
Europe
LiPlaCis, Irofulven, 2X-121, Concentrate for dispersion for infusion, Concentrate for solution for infusion, Capsule, hard
Vejle Hospital, Vejle Hospital, Oncology Venture
Breast cancer Ovarian cancer Lung cancer Colorectal cancer Prostate cancer Pancreatic cancer, Breast cancer Ovarian cancer Lung cancer Cancer of the colon and rectum Prostate cancer Pancreatic cancer, Diseases [C] - Cancer [C04]
 
 
PREDICT 2X-121, NCT03878849: Investigation of the Anti-tumor Effect of 2X-121 in Patients With Recurrent, Advanced Ovarian Cancer

Active, not recruiting
2
40
US
2X-121, E7449, MGI25036
Allarity Therapeutics, Alcedis GmbH, Amarex Clinical Research
Advanced Ovarian Cancer
03/27
09/27
NCT03562832 / 2017-003508-39: Investigation of Anti-tumour Effect and Tolerability of the PARP Inhibitor 2X-121 in Patients With Metastatic Breast Cancer Selected by the 2X-121 DRP

Active, not recruiting
2
30
Europe
PARP inhibitor 2X-121
Allarity Therapeutics, Smerud Medical Research International AS, Danish Breast Cancer Cooperative Group
Metastatic Breast Cancer
04/24
08/24
Relapsed SCLC, NCT06681220: Biomarker Directed Trial of Temozolomide and Stenoparib in

Not yet recruiting
1/2
166
US
Stenoparib/Temozolomide, Stenoparib/TEMODAR, Lurbinectedin, Zepzelca
VA Office of Research and Development
Relapsed Small Cell Lung Cancer, Recurrent Small Cell Lung Cancer
12/29
12/30
NCT05571969: Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Suspended
1
40
US
2X-121 and dovitinib
Allarity Therapeutics, Amarex Clinical Research
Advanced Solid Tumors
10/24
12/25
dovitinib (TKI258) / Novartis, Oncoheroes
No trials found

Download Options